Gastroenterologist Rory V. O'Connor, MD, has announced the closing of his private practice, Eastern Carolina Gastroenterology, according to a Roanoke Rapids Daily Herald report.
Author: Staff
Rochester, N.Y.-based ophthalmologic device and supply company Bausch + Lomb announced it has completed its acquisition of Technolas Perfect Vision, a German company based in Munich that manufactures lasers used in cataract and refractive surgery.
The Moran Eye Center, part of the University of Utah Health System in Salt Lake City, performed free eye surgery for a dozen poor and uninsured patients suffering from cataracts and similar ailments.
Ophthalmic Consultants of Long Island, a group of 26 physicians based in and around New York City, announced it will be among 14 initial sites across the country surgically implanting an ocular telescope device in elderly patients suffering from age-related…
Eye health company Bausch + Lomb, based in Rochester, N.Y., announced it had begun the third phase of testing for latanoprostene bunod, a drug it is licensing from Paris-based Nicox for experimental use in patients with glaucoma or ocular hypertension.
Advertisement
The recent fiscal cliff deal has many implications for surgeons both professionally and personally, including tax increases. Roll backs from the Bush Tax Cuts include a 4.5 percent tax rate increase for wealthy Americans and separate from the fiscal cliff…
novoGI announced it has signed an agreement with Endopix for the right to market, distribute, sell and support a novoGI-branded product based on next-generation video enhancement software in the fields of gastroenterology.
novoGI announced it has signed an agreement with Endopix for the right to market, distribute, sell and support a novoGI-branded product based on next-generation video enhancement software in the fields of gastroenterology.
Purdue Pharma in Stamford, Conn., a pharmaceutical company, and EIMindA in Israel, a company that develops brain functional mapping technology, have entered into a multi-year research collaboration agreement.
An FDA advisory panel has voted in favor of moving hydrocodone combination products, including Vicodin, Lortab and Norco, into the more restrictive Schedule II category of controlled substances, according to a report by The Clinical Advisor.